Hutchmed says FDA grants orphan drug designation to sovleplenib
HCM•Hutchmed said the FDA granted orphan drug designation to sovleplenib for primary immune thrombocytopenia.
1. Drug designation
Hutchmed announced that the FDA granted orphan drug designation to sovleplenib in primary immune thrombocytopenia.
